Display options
Cite
Maina I, Rule JA, Wians FH, et al. α-Glutathione S-Transferase: A New Biomarker for Liver Injury?. J Appl Lab Med. 2016;1(2):119-128doi: 10.1373/jalm.2016.020412.
Maina, I., Rule, J. A., Wians, F. H., Poirier, M., Grant, L., & Lee, W. M. (2016). α-Glutathione S-Transferase: A New Biomarker for Liver Injury?. The journal of applied laboratory medicine, 1(2), 119-128. https://doi.org/10.1373/jalm.2016.020412
Maina, Ian, et al. "α-Glutathione S-Transferase: A New Biomarker for Liver Injury?." The journal of applied laboratory medicine vol. 1,2 (2016): 119-128. doi: https://doi.org/10.1373/jalm.2016.020412
Maina I, Rule JA, Wians FH, Poirier M, Grant L, Lee WM. α-Glutathione S-Transferase: A New Biomarker for Liver Injury?. J Appl Lab Med. 2016 Sep 01;1(2):119-128. doi: 10.1373/jalm.2016.020412. PMID: 33626782.
Copy Download .nbib Format: NLM
Share it on

J Appl Lab Med. 2016 Sep 01;1(2):119-128. doi: 10.1373/jalm.2016.020412.

α-Glutathione S-Transferase: A New Biomarker for Liver Injury?.

The journal of applied laboratory medicine

Ian Maina, Jody A Rule, Frank H Wians, Michael Poirier, Lafaine Grant, William M Lee

Affiliations

  1. Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX.
  2. Texas Tech University Health Sciences Center, El Paso, TX.
  3. Qualigen, Carlsbad, CA.

PMID: 33626782 DOI: 10.1373/jalm.2016.020412

Abstract

BACKGROUND: Serum alanine and aspartate aminotransferases (ALT/AST) have been the gold standard for detection and quantification of liver injury for over 6 decades, but have relatively long half-lives (T½) (literature estimates approximately 17 and 47 h, respectively) and thus do not reflect immediate changes in liver injury or recovery. A new point-of-care immunoassay for α-glutathione S-transferase (α-GST) measures this cytosolic liver enzyme with a predicted T½ of 60-90 min based on preliminary studies and might enable earlier detection of improving or worsening liver injury than conventional enzyme testing.

METHODS: Serial serum samples collected daily from 31 patients enrolled in the Acute Liver Failure Study Group, with acetaminophen (APAP) toxicity, drug-induced liver injury, ischemic hepatopathy (IH), or autoimmune hepatitis were analyzed to determine α-GST using the Qualigen FastPack® α-GST Assay (Carlsbad), a chemiluminescent immunoassay using a paramagnetic particle matrix with an upper limit of normal of 11 ng/mL. AST and ALT values were obtained from the medical record and have an upper limit of normal of 40 IU/L. The T½ values for α-GST, AST, and ALT were calculated from the peak value for APAP and IH etiologies considered as single time point injuries, using an exponential trendline equation of the serial values.

RESULTS: Median α-GST for all etiologies were increased on day 1, returning to normal by day 3, whereas median AST and ALT values did not return to normal, even at day 7. The median T½ for α-GST, AST, and ALT were 6.4, 22.2, and 33.9 h, respectively.

CONCLUSIONS: α-GST is a more responsive marker of liver injury/recovery, allowing for more rapid real-time assessment of improvement or worsening of liver disease.

© 2016 American Association for Clinical Chemistry.

Publication Types